ClinicalTrials.gg
CompletedNCT03813992Updated Mar 2, 2022

Clinical Trial Using Topically Applied Glyceryl Trinitrate (GTN) for the Treatment of Erectile Dysfunction

A Phase 3 interventional study of MED2005 in Erectile Dysfunction, sponsored by Futura Medical Developments Ltd.. Completed at 53 sites in 9 countries. Open to male participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-03-02.

Sponsored by Futura Medical Developments Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,005
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Erectile Dysfunction with a site in Russian Federation — 2 open to participants now, 2 under way, none of them phase 3. Erectile Dysfunction · Russian Federation.

Enrollment
Largest of 14
1,005 · median 251
Started
2018
with 1 other
Phase 3
6 of 15
none open now
Registered
12th of 15
by date
Lead sponsor
1 of 15
Futura Medical Developments Ltd.

Among the 15 studies in Erectile Dysfunction with a site in Russian Federation, this one has the largest enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2018, is one of 6 in phase 3, and was the 12th registered.

Erectile Dysfunction

702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.

Browse Erectile Dysfunction studies →

Open to participants now

2 of the 15 studies in Erectile Dysfunction with a site in Russian Federation are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →

Who these studies take

Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 70 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Erectile Dysfunction with a site in Russian Federation, or all of them as a file.
02

Study summary

To demonstrate the efficacy of various doses of MED2005 versus placebo in male patients with clinically diagnosed erectile dysfunction, and to evaluate the long-term efficacy and safety (12 months) of MED2005.

Read the detailed description

A phase III, dose-ranging, multi-centre, randomised, double-blind, placebo controlled , home-use, parallel group clinical trial of topically applied glyceryl trinitrate for the treatment of erectile dysfunction with an open label extension

03

Conditions studied

  • Erectile Dysfunction

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is a male aged between 18 and 70 years inclusive, at screening
  2. Confirmed clinical diagnosis of ED for more than 3 months according to the NIH Consensus Statement ('the inability to achieve or maintain penile erection sufficient for satisfactory sexual performance at least once')
  3. Subject answers 'yes' to the question regarding the presence of residual EF over the past 3 months: 'At home over the past 3 months, have you experienced at least some growth of your penis in response to: (1) mechanical stimulation by yourself or your partner, or (2) visual stimulation?'
  4. Subject has been involved in a continuous heterosexual relationship for at least 6 months prior to screening
  5. Documented written from both subject and his female partner
  6. If the male subject's female partner is of from the time of first sexual intercourse attempt during the screening period until the last administration of study treatment, then the couple must have been using a medically acceptable form of for at least 3 months prior to entering the study, and agree to continue such use for at least 1 month after the last study drug administration. Subjects who are or wish to become pregnant will not be included in the study.
  7. Subject and his female partner are capable of understanding and complying with the requirements of the protocol and must have signed the ICF prior to participation in any study related procedures
  8. Low IIEF-EF scores (≤ 25) during the screening period

To continue in the open-label extension phase of the study, subjects must meet the following inclusion criteria at the follow-up visit of the double-blind phase (Visit 6):

  1. Subject and his female partner complete the double-blind phase
  2. Subject and his female partner were compliant to study procedures during the double blind phase
  3. Documented written informed consent from both subject and his female partner
  4. If the male subject's female partner is of childbearing potential from the time of first sexual intercourse attempt during the screening period until the last administration of study treatment, then the couple must have been using a medically acceptable form of contraception for at least 3 months prior to entering the study, and agree to continue such use for at least 1 month after the last study drug administration. Subjects who are or wish to become pregnant will not be included in the study.

Exclusion criteria

Exclusion Criteria:

  1. Any significant or serious cardiovascular, pulmonary, hepatic, renal, gastrointestinal, haematological, endocrinological, metabolic, neurological or psychiatric disease which, in the opinion of the PI, renders the subject unfit to take part in the study
  2. Subject has any history of an unstable medical or psychiatric condition or using any medication that, in the opinion of the PI, is likely to affect the subject's ability to complete the study or precludes the subject's participation in the study Certain concomitant medications; e.g. other vasodilators, calcium channel blockers, angiotensin converting enzyme (ACE) inhibitors, beta blockers, diuretics, anti hypertensives, tricyclic anti depressants and major tranquillisers, as well as the consumption of alcohol, may potentiate the BP lowering effects of MED2005; therefore, the PI must consider this carefully and include subjects at their discretion
  3. Any presence of a symptomatic, active urinary tract infection diagnosed by the PI or their delegate at screening or during the study
  4. Any presence of chronic indwelling urethral catheterisation or penile anatomical abnormalities (e.g. penile fibrosis) that would significantly impair EF
  5. Any history of operations for Peyronie's disease
  6. Primary hypoactive sexual desire or any history of hypogonadism
  7. Any history of radical prostatectomy
  8. Any history of severe/uncontrolled diabetes
  9. Subjects taking two or more anti hypertensives for the treatment of BP
  10. to GTN or to any of the , or idiosyncratic reactions to other organic nitrates
  11. Concomitant treatment with sildenafil citrate, tadalafil, vardenafil and other PDE 5 inhibitors
  12. Subjects taking Alpha blockers
  13. Subjects receiving testosterone pellets
  14. Any penile surgery except circumcision
  15. Any treatment with acetyl cysteine within 6 months
  16. Any treatment with dihydroergotamine within 6 months
  17. Postural hypotension, hypotension or uncorrected hypovolaemia, as the use of GTN in such states could produce severe hypotension or shock
  18. Increased intracranial pressure (e.g. head trauma or cerebral haemorrhage) or inadequate cerebral circulation
  19. Any history of migraine or recurrent headache
  20. Aortic or mitral stenosis
  21. Hypertrophic obstructive cardiomyopathy
  22. Constrictive pericarditis or pericardial tamponade
  23. Closed-angle glaucoma
  24. Subjects with nursing partners, known pregnant partners or with partners who wish to become pregnant during the course of the study
  25. Confirmed positive results from urine drug screen (amphetamines, benzodiazepines, cocaine, cannabinoids, opiates, barbiturates, tricyclic antidepressants and methadone) or from the alcohol breath test at screening (for clarification, any positive result from the urine drug screen or alcohol breath tests at screening will mean the subject will be excluded from the study). In the instance that a subject is using medication which may give a positive result, exclusion will be at the PI's discretion
  26. Subject has recent (last 12 months) clinical evidence of alcoholism or drug abuse.
  27. Subject has a positive screen for , consisting of hepatitis B surface antigen (HBsAG), antibody, and (HIV)
  28. Any abnormal laboratory, vital signs or other safety findings as determined by medical history, physical examination or other evaluations conducted at screening or on admission
  29. Subjects unwilling to cease use of vacuum devices, intracavernosal injections, PDE-5s or other therapy for ED for the entire course of the study
  30. Unwillingness of the subject or their partner to agree to make the required attempts at sexual intercourse during treatment period
  31. Any history of unresponsiveness to PDE 5 treatment or significant side effects, excluding visual disturbances, with PDE 5s
  32. Fewer than four attempts at sexual intercourse during the screening period
  33. Subjects or their partners who are illiterate or are unable to understand the language in which the questionnaires are available
  34. Subject has received any product during the 90 days prior to dosing for this study
  35. Subject or his partner cannot communicate reliably with the PI
  36. Subjects with severe premature ejaculation (little or no control of ejaculation at the time of penetration)

Subjects are prohibited from participating in the open-label extension phase of the study if they meet any of the following exclusion criteria at the follow-up visit of the double-blind phase (Visit 6):

  1. Subsequent to recruitment into the double-blind phase of the study, the development of any significant or serious cardiovascular, pulmonary, hepatic, renal, gastrointestinal, haematological, endocrinological, metabolic, neurological or psychiatric disease which, in the opinion of the PI, renders the subject unfit to continue in the open-label extension phase of the study
  2. Subject using any medication that, in the opinion of the PI, is likely to affect the subject's ability to complete or participate in the open-label phase of the study.

    NB The concomitant medications listed as exclusion criteria for the study apply to the open-label extension phase. Certain concomitant medications; e.g. other vasodilators, calcium channel blockers, ACE inhibitors, beta blockers, diuretics, anti hypertensives, tricyclic anti depressants and major tranquillisers, as well as the consumption of alcohol, may potentiate the BP lowering effects of MED2005; therefore, the PI must consider this carefully and include subjects at their discretion

  3. Any presence of a symptomatic, active urinary tract infection diagnosed by the PI or their delegate at the start of the open-label extension phase
  4. Subsequent to recruitment into the double-blind phase of the study, the development of postural hypotension, hypotension or uncorrected hypovolaemia, increased intracranial pressure or inadequate cerebral circulation, any clinically significant vital signs or other safety findings as determined by medical history, physical examination or other evaluations conducted at Visit 6 prior to recruitment to the open-label phase
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,005 participants (actual)

Study arms

  • Active comparator
    MED2005 0.2%

    MED2005 0.2% w/w gel to deliver 0.6 mg dose of GTN applied topically prior to a sexual intercourse attempt

    Drug: MED2005

  • Active comparator
    MED2005 0.4%

    MED2005 0.4% w/w gel to deliver 1.2 mg dose of GTN applied topically prior to a sexual intercourse attempt

    Drug: MED2005

  • Active comparator
    MED2005 0.6%

    MED2005 0.6% w/w gel to deliver 1.8 mg dose of GTN applied topically prior to a sexual intercourse attempt

    Drug: MED2005

  • Placebo comparator
    Placebo vehicle

    Placebo vehicle applied topically prior to a sexual intercourse attempt

    Drug: MED2005

Interventions

  • Topical Product

    Also known as: Glyceryl Trinitrate

06

What researchers measure

Primary outcomes

  1. International Index for Erectile Function (IIEF) Questionnaire

    A questionnaire containing 15 questions divided into 5 domains; erectile function, orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction.

    Time frame: Up to Week 64 of the study

  2. Sexual Encounter Profile (SEP) Questionnaire (Question 2)

    A questionnaire consisting of 5 items assessing the sexual events a patient experiences during sexual intercourse.

    Time frame: Up to Week 64 of the study

  3. Sexual Encounter Profile (SEP) Questionnaire (Question 3)

    A questionnaire consisting of 5 items assessing the sexual events a patient experiences during sexual intercourse.

    Time frame: Up to Week 64 of the study

Secondary outcomes

  1. Self-Esteem and Relationship (SEAR) Questionnaire

    A questionnaire to support the validity and reliability for measuring sexual relationship satisfaction, satisfaction, confidence, and self-esteem in men with erectile dysfunction.

    Time frame: Up to Week 12 of the study.

  2. Global Assessment Questionnaire (GAQ)

    A questionnaire that allows patients and their partners to rate (yes or no) an improvement in erectile function.

    Time frame: Up to Week 12 of the study.

  3. International Index for Erectile Function (IIEF) Questionnaire (additional domains)

    A questionnaire containing 15 questions divided into 5 domains; erectile function, orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction.

    Time frame: Up to Week 64 weeks of the study.

  4. Sexual Encounter Profile (SEP) Questionnaire (Questions 1, 4 & 5)

    A questionnaire consisting of 5 items assessing the sexual events a patient experiences during sexual intercourse.

    Time frame: Up to Week 64 of the study.

  5. Sexual Encounter Profile (SEP) Questionnaire

    A questionnaire consisting of 5 items assessing the sexual events a patient experiences during sexual intercourse.

    Time frame: Up to Week 64 of the study

  6. Patient Global Impression of Severity (PGI-S)

    A one item questionnaire to rate the severity of a patient's erectile dysfunction. This is a single-state 5-point categorical scale.

    Time frame: Up to Week 12 of the study.

  7. Patient Global Impression of Change (PGI-C)

    A one item questionnaire to rate a perceived change in a patient's erectile function. This is a transitional 7-point categorical scale.

    Time frame: Up to Week 12 of the study

  8. Onset and duration of action (erection) and erection hardness

    A questionnaire asking both the patient and the patient's partner about the onset and duration of action of the patient's erection.

    Time frame: Up to Week 12 of the study

  9. Usage and application

    A questionnaire has 5 items to assess the usage and application of the investigation product.

    Time frame: Up to Week 12 of the study

07

Study locations

53 sites
  • UMHAT Burgas EAD
    Burgas, Bulgaria
  • Multiprofile Hospital for Active Treatment
    Pleven, Bulgaria
  • University Multiprofile Hospital for Active Treatment
    Plovdiv, Bulgaria
  • Urology Office Diagnostic-Consultative Center
    Varna, Bulgaria
  • Medical Center Biomed
    Vidin, Bulgaria
  • URAN MUDr.Jan Hiblbauer s.r.o
    Hradec Králové, Czechia
  • ANDROGEOS, spol. s.r.o.
    Praha, Czechia
  • Urosante s.r.o.
    Praha, Czechia
  • LTD Gormedi
    Gori, Georgia
  • LTD Gidmedi
    Tbilisi, Georgia
  • LTD Multiprofile Clinic Consilium Medulla
    Tbilisi, Georgia
  • LTDHealth House
    Tbilisi, Georgia
  • Synexus Magyarorszag Kft
    Budapest, Hungary
  • Civis Egeszseghaz
    Debrecen, Hungary
  • Korona Prevent-Med Kft.
    Sopron, Hungary
  • Aranyklinika
    Szeged, Hungary
  • Latgales Urology Center
    Daugavpils, Latvia
  • V. Lietuviesa Private Practice
    Riga, Latvia
  • Vidzemes Hospital
    Valmiera, Latvia
  • Indywidualna Specjalistyczna Praktyka Lekarska Dr Adam Sipinski
    Katowice, Poland
  • PROVITA Specjalistyczna Praktyka Ginekologiczno-Seksuologiczna
    Lublin, Poland
  • Indywidualna Specjalistyczna Praktyka Lekarska
    Szczecin, Poland
  • Gabinet Lekarski Ryszard Smolinski
    Wrocław, Poland
  • Regional Budgetary Healthcare Institution "Ivanovskaya Regional Clinical Hospital"
    Ivanovo, Russian Federation
  • CJSC "Nasledniki"
    Moscow, Russian Federation
  • Federal State Budgetary Institution "National Medical Research Center of Obstetrics, Gynecology and Perinatology n.a. acad. V.I. Kulakov" of the Ministry of Healthcare of the Russian Federation
    Moscow, Russian Federation
  • FSBEI HE "Russian National Research Medical University n.a. N.I. Pirogov" of the Ministry of Healthcare of the Russian Federation, Russian Gerontological Scientific and Research Center
    Moscow, Russian Federation
  • LLC "Bessalar Clinic"
    Moscow, Russian Federation
  • LLC "Unimed-S"
    Moscow, Russian Federation
  • State Budgetary Institution "Hospital for War Veterans"
    Rostov-on-Don, Russian Federation
  • Federal State Budgetary Educational Institution of Higher Education "North-Western State Medical University n.a. I.I. Mechnikov" of the Ministry of Healthcare of the Russian Federation
    Saint Petersburg, Russian Federation
  • LLC "Medical center PRIME ROSE"
    Saint Petersburg, Russian Federation
  • LLC "Sanavita"
    Saint Petersburg, Russian Federation
  • Llc <<Mart>>
    Saint Petersburg, Russian Federation
  • Medicosanitary Department No.70, branch of Saint-Petersburg State Unitary Institution of road passenger transport
    Saint Petersburg, Russian Federation
  • Research Center "Eco-Safety"
    Saint Petersburg, Russian Federation
  • Saint Petersburg State Budgetary Healthcare Institution "City Polyclinic No. 4"
    Saint Petersburg, Russian Federation
  • Clinical Hospital n.a. S.R. Mirotvortseva of the Federal State Budgetary Educational Institution of Higher Education "Saratovskiy State Medical University n.a. V.I. Razumovskiy" of the Ministry of Healthcare of the Russian Federation
    Saratov, Russian Federation
  • Federal State Budgetary Educational Institution of Higher Education " Voronezhskiy State Medical University n.a. N.N. Burdenko" of the Ministry of Healthcare of the Russian Federation on the clinical base of Budgetary Healthcare Institution of Voronezhsk
    Voronezh, Russian Federation
  • SBHI of Leningradskaya region "Vsevolozhskaya Clinical Interdistrict Hospital"
    Vsevolozhsk, Russian Federation
  • FSBEI HPE "Yaroslavskiy State Medical University" of The Ministry of Healthcare of the Russian Federation with clinical base in State Autonomous Institution of Yaroslavskaya region "Clinical Hospital No.9"
    Yaroslavl, Russian Federation
  • Urologicka ambulancia
    Košice, Slovakia
  • Urologicka ambulancia Urobet s.r.o.
    Malacky, Slovakia
  • Urologicka ambulancia Uroexam s.r.o.
    Nitra, Slovakia
  • Privatna urologicka ambulancia s.r.o.
    Trenčín, Slovakia
  • Municipal Establishment "Cherkasy Regional Hospital of Cherkasy Regional Council", Urology department
    Cherkasy, Ukraine
  • Regional Clinical Hospital, Polyclinic Department
    Ivano-Frankivs'k, Ukraine
  • Kyiv Clinical Hospital on Railway Transport #1 of the branch "Health Center" of the public joint stock company "Ukrainian Railway", consulting and diagnostic center
    Kyiv, Ukraine
  • State Institution "Institute of urology of the National Academy of Medical Science of Ukraine", policlinic department
    Kyiv, Ukraine
  • State Institution "Institute of urology of the National Academy of Medical Sciences of Ukraine", Department of Sexual Pathology and Andrology
    Kyiv, Ukraine
  • "Ambulatory of General Practice-Family Medicine",LLC, Medical Center
    Odesa, Ukraine
  • Private Small-Scale Enterprise Medical Centre "Pulse" , Therapeutic Department
    Vinnytsia, Ukraine
  • Municipal Institution Central City Hospital №1 of Zhytomyr, consulting and medical department "Research center"
    Zhytomyr, Ukraine
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Jul 2019, 8 months.

Of 16 phase 3 interventional studies under Erectile Dysfunction, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 30. This study's 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2019
First posted
Jan 23, 2019
StartActual
Nov 1, 2018
Primary completionActual
Jul 21, 2019
CompletionActual
Jan 17, 2020
Last update
Mar 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03813992
Lead sponsor
Futura Medical Developments Ltd.
Responsible party
Sponsor
First posted
Jan 23, 2019
Start date
Nov 1, 2018
Primary completion
Jul 21, 2019
Completion
Jan 17, 2020
Last update
Mar 2, 2022

Study contacts

Tim J Holland, MBA
study director · Clinical Development Director

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nitroglycerin

Start the discussion